We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Plague Detected by Anti-Carbohydrate Antibodies

By LabMedica International staff writers
Posted on 07 Aug 2013
A diagnostic test for detecting the presence of Yersinia pestis, the cause of plague, may soon be easier than ever before. More...


The presence of antibodies against a surface glycan in the blood of infected patients can be a biomarker of diagnostic value in Y. pestis infections.

A scientific team at the Max Planck Institute (Potsdam, Germany) developed a simple, inexpensive, and reliable method of detecting the bacterium. They identified and synthesized an oligosaccharide structure on bacterial surface before combining it with a protein to heighten the immunological effect. The presence of antibodies against this surface glycan in the blood of infected patients can be a biomarker of diagnostic value in Y. pestis infections. The scientists also used the antigen to create antibodies, which can directly detect the plague pathogen in infected samples.

The antibodies can identify plague bacteria with high selectivity and accuracy without the result being distorted by other bacteria biochemically related to plague, and therefore the scientists have effectively produced a quick test for this deadly disease. The glycan or its glycoconjugates can be applied to test strips where it acts as an antigen and catches antibodies from the blood of infected patients. The antigen-antibody complexes are very easy to detect with fluorescing proteins. The antibodies could provide a way of directly detecting the plague pathogen in infected tissue, by using fluorescing proteins to identify whether the antibodies have docked onto the bacterial surface. Antibody binding assays were performed using synthetic carbohydrate antigen-based microarrays and slides were scanned using a GenePix 4300A scanner (Bucher Biotec; Basel, Switzerland).

Peter H. Seeberger, PhD, Director at the Max Planck Institute of Colloids and Interfaces, said, “These reliable tests are simple and economical to administer. This gives the new approach major advantages over the testing methods used to date. In the past, plague pathogens were detected by phenotyping or gene testing. The problem with these methods is that they are complex, expensive, and slow, and, what's more, they have a high failure rate.” The study was published on July 10, 2013, in the journal Angewandte Chemie International.

Related Links:

Max Planck Institute

Bucher Biotec



Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
High-Density Lipoprotein Containing Cholesterol Assay
HDL-c direct FS
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.